**Message from the Program Director**

The mission of the Cancer Risk Assessment and Clinical Cancer Genetics Program, which launched in late 2014, is to offer comprehensive expert genetic counseling, advanced genetic testing, and novel research opportunities to all patients concerned about cancer risk for themselves and their families. We evaluate patients with all types of cancers, with or without medical risk factors, cancer family history, and primary medical care. For patients to make an informed decision about genetic testing, we review every case at our weekly Genetics Case Conference which includes genetic counseling and testing process based around family history sequencing.

**Philanthropy**

Philanthropic funds are a vital link to keep the innovative research and patient-centered initiatives moving forward. If you are interested in learning more about our program or to make a donation, please contact Laura Gross at 215-513-9286.

**For more information about our Cancer Risk Assessment and Clinical Cancer Genetics Program or to refer a patient, contact Karen E. Fidina at 215-513-1013 or kane@sidneykimmel.edu**

**SPRING 2017**

**Sidney Kimmel Cancer Center at Jefferson**

**Cancer Risk Assessment and Clinical Cancer Genetics Program**

**Sidney Kimmel Cancer Network and Cancer Genetics**

We are currently providing genetic services for the following Jefferson Health and Sidney Kimmel Cancer Network Members:

- Arabs – Jefferson Health
- Mercy Health System (Mercy Fitzgerald and Nazareth)
- Delaware Medical, PC, Nazareth
- Horizon University Hospital, Sewell, NJ
- Doylestown Hospital, Doylestown, PA

**KARE Study/Inherited Cancer Risk Study**

This study is exploring genetic counseling and testing in the new era of tumor sequencing potentially informing inherited cancer risk. The goal is to characterize the inherited mutation spectrum, correlation to personal and family history, and assess genetic providers and patients regarding their knowledge, confidence, and satisfaction with the genetic counseling and testing process based around tumor sequencing.

**Telegenetics**

An in effort to expand access to our cutting-edge cancer genetics programs, we have launched our Telegenetics initiative. This tele-health approach provides patients the option to have genetic counseling remotely via a secure, web-based application in order to maximize access to our program. Patients will also have opportunities to engage in research through the research initiative.

**Cancer Disparities**

- Cancer risk assessment knowledge, attitudes, and uptake projects are being developed and tested for minority populations who experience higher rates of cancer, such as African American, Latino, and Asian American populations. In order to assure the genetic counseling process is relevant and inclusive, we are developing models and enrolling individuals into research studies to get much-needed insights regarding the genetic contribution to cancer risk in diverse populations.

**Innovation Arm Initiatives**

- Genetic Evaluation of Men (GEM) Registry – A registry of men with and at risk for prostate cancer. We collect medical, family history, behavioral data as well as DNA for cancer research risk. We are exploring the role of genetic, race, environment, and lifestyle factors in cancer development in patients and their families. We develop the field of genetic testing for prostate cancer. This is the first prostate cancer GEM registry.
- **GU Multigene Testing Study**
  - This initiative is building upon the existing peer-support program for patients to focus on patients with prostate cancer. We assess all patients with and without who have undergone genetic counseling in cancers to determine to provide peer support to patients and their families.

**Network Members:**

We are currently providing cancer genetic services for any cancer or at-risk individuals evaluated for genetic risk. We will collect medical, family history, behavioral data as well as DNA for cancer research risk and also be exploring the role of gene-environment and lifestyle factors in cancer development in patients and their families.

**Genetics Buddy Program**

This initiative is building upon the existing peer-support program for patients to focus on patients with prostate cancer. We assess all patients with and without who have undergone genetic counseling in cancers to determine to provide peer support to patients and their families.

**Cancer Risk Assessment and Clinical Cancer Genetics Program**

**The mission of the Cancer Risk Assessment and Clinical Cancer Genetics Program, which launched in late 2014, is to offer comprehensive expert genetic counseling, advanced genetic testing, and novel research opportunities to all patients concerned about cancer risk for themselves and their families. We evaluate patients with all types of cancers, with or without medical risk factors, cancer family history, and primary medical care.**

**Philanthropy**

Philanthropic funds are a vital link to keep the innovative research and patient-centered initiatives moving forward. If you are interested in learning more about our program or to make a donation, please contact Laura Gross at 215-513-9286.

**For more information about our Cancer Risk Assessment and Clinical Cancer Genetics Program or to refer a patient, contact Karen E. Fidina at 215-513-1013 or kane@sidneykimmel.edu**
Colette Inglis, MS, LGC

Colette Inglis has been a practicing genetic counselor specializing in hereditary breast and ovarian cancer. She earned her Bachelor of Science in Biology from the University of Maryland in 2009 and her Master of Science in Genetic Counseling from the University of Central Florida in 2011. Colette works as a genetic counselor in hereditary breast and ovarian cancer at the Sidney Kimmel Cancer Center at Jefferson.

Laura Gross, BA

Laura Gross became program manager for the Clinical Cancer Genetics Program in 2014. After receiving a biology degree from Rutgers University, she began her career in cancer research as a research assistant in a tumor immunology laboratory concentrating on melanoma. After working in the lab for 10 years, Laura saw that the field was in need of patient interaction, and took on the role of project manager for a research study providing prostate cancer screening for men at high-risk for prostate cancer. During this time, she developed an interest in the genetic evaluation for inherited cancer risk for all types of cancers. As program manager for the Clinical Cancer Genetics Program, Laura works closely with genetic providers and coordinates all of Dr. Gail’s research studies, focusing on cancer risk, genetic counseling, and genetic testing, screening, and prevention. She also coordinates summer internships for high school and college students to engage in cancer research at the Sidney Kimmel Cancer Center at Jefferson.

Karen Robinson, CMA

Karen Robinson joined The Cancer Risk Assessment and Counseling in 2014, and serves as the Patient Intake Coordinator. Karen has a Certified Medical Assistant with experience in oncology care. She has been with Thomas Jefferson University Hospital at New York Presbyterian/Hospital. Dr. Jaslow specializes in treating patients with breast and ovarian cancers and provides management expertise for patients at high-risk for breast and ovarian cancers.

Rebecca Jaslow, MD

Rebecca Jaslow, MD, is an Assistant Professor in Medical Oncology at Sidney Kimmel Cancer Center at Jefferson. She received her medical degree from Columbia School of Medicine at Mount Sinai in 1996. Prior to her current position, she worked in clinical research for breast and ovarian cancers. She is also the director of Basic Science and Research in Medical Oncology as well as the leader of the Breast Cancer Program at SKCC. She received her medical degree from University of California, San Francisco. She completed her residency at the University of California, San Francisco, and her fellowship in Medical Oncology at the Dana-Farber Cancer Institute. Dr. Silver specializes in treating patients with breast cancer and those at high-risk for breast cancer; he contributes his expertise in breast cancer treatment and high-risk management to the Clinical Cancer Genetics Program.

Daniel Silver, MD, PhD

Daniel Silver, MD, PhD, is an Associate Professor in the departments of Medical Oncology and Cancer Biology at the Sidney Kimmel Cancer Center at Jefferson. He is also the director of Basic Science and Research in Medical Oncology as well as the leader of the Breast Cancer Program at SKCC. He received his medical degree from the University of California, San Francisco. He completed his residency at the University of California, San Francisco, and his fellowship in Medical Oncology at the Dana-Farber Cancer Institute. Dr. Silver specializes in treating patients with breast cancer and those at high-risk for breast cancer; he contributes his expertise in breast cancer treatment and high-risk management to the Clinical Cancer Genetics Program.